AdvisorShares Pure US Cannabis ETF

MSOS

Market cap $744M

Overview Fund Activity

4.20 USD

-0.18

4.11%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

4.30

+0.10

2.38%

1 day

-4.11%

5 days

-12.13%

1 month

-9.48%

3 months

87.5%

6 months

48.41%

Year to date

2.94%

1 year

-37.96%

5 years

-81.16%

10 years

-82.98%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

360% more call options, than puts

Call options by funds: $15.3M | Put options by funds: $3.32M

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

3% less funds holding

Funds holding: 154 [Q1] → 150 (-4) [Q2]

2.88% less ownership

Funds ownership: 25.53% [Q1] → 22.65% (-2.88%) [Q2]

10% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 20

10% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 40

20% less capital invested

Capital invested by funds: $90.5M [Q1] → $72.3M (-$18.2M) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 4 articles about MSOS published over the past 30 days

Quant Buys In Cannabis

Cannabis has bipartisan support, but is it worthy of your investment? Quant Strategist Emma Johnston on how quant thinks about sector ETF MSOS, currently rated a buy due to strong momentum and liquidity, with high regulatory risk.

Quant Buys In Cannabis

MSOS: Cannabis Investors Betting Big On Trump

Optimism that the Trump administration will soon reschedule cannabis, thereby removing the Section 280E tax burden and boosting sector profitability, has fueled a dramatic rally in cannabis stocks. MSOS ETF saw a 27.2% increase in shares outstanding and inflows of about $165 million since July, reflecting surging investor interest in U.S. cannabis stocks. MSOS aggressively increased positions in key cannabis companies, with notable additions and significant percentage increases in holdings across its portfolio.

MSOS: Cannabis Investors Betting Big On Trump

Proactive Investors

US cannabis stocks rally as Trump backs rescheduling

Investors are closely watching the US cannabis space after President Donald Trump signaled plans to reschedule marijuana, a move that is expected to unlock near-term financial relief and longer-term growth for the industry. Trump recently stated that his administration will “be moving forward soon with rescheduling marijuana,” referring to its reclassification as a lower-risk Schedule III drug.

US cannabis stocks rally as Trump backs rescheduling

Disruptive Theme of the Week: Cannabis Staging a Comeback

Cannabis ETF spent the first half of the year in the performance doldrums. But they have rallied of late on news that the Trump administration is open to reclassifying marijuana as a less dangerous drug.

Disruptive Theme of the Week: Cannabis Staging a Comeback

Rescheduling Should Send MJ And MSOS Sky High

Cannabis stocks and ETFs like Amplify Alternative Harvest ETF and AdvisorShares Pure US Cannabis ETF are surging on speculation that President Trump will reclassify marijuana as a Schedule III drug. Rescheduling would reduce regulatory and banking risks, potentially unlocking new capital and investor interest, but both ETFs carry high fees and concentration risks. MJ is preferred over MSOS for its greater diversification, though both face challenges from high expense ratios and reliance on swaps.

Rescheduling Should Send MJ And MSOS Sky High

CNBC Television

Cannabis stocks rally after Trump says he is weighing drug reclassification

Cannabis stocks rallied Monday after President Donald Trump said he is considering reclassifying marijuana, which would categorize it as less of a danger to public safety.

Cannabis stocks rally after Trump says he is weighing drug reclassification

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

Cannabis stocks rallied on a Wall Street Journal report that President Donald Trump is contemplating reclassifying weed as having a lower danger level. Such a move would be "a gamechanger" for the industry, one investing chief said.

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

Zacks Investment Research

Best-Performing ETF Areas of Last Week

Trump's sweeping new tariffs on Canada, the EU, and Mexico weight on markets slightly last week. However, crypto (i.e.

Best-Performing ETF Areas of Last Week

MSOS: Headed For A New All-Time Low

MSOS has significantly underperformed the broader cannabis market, dropping 41.2% YTD versus a 27.8% sector decline. I downgraded MSOS to Strong Sell in April due to persistent risks, and the ETF has continued to fall since then. Key concerns include poor chart performance, plunging trading volume, high portfolio concentration, and waning investor interest in multi-state operators.

MSOS: Headed For A New All-Time Low

MSOS ETF Underperforms Compared To Canadian Cannabis Peers

MSOS holds US cannabis MSOs exclusively. It allows for exposure to US cannabis companies. US MSO stocks are historically down.

MSOS ETF Underperforms Compared To Canadian Cannabis Peers

See News Rankings

Charts implemented using Lightweight Charts™